Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Trident Group Eyes €13bn+ EU Home Textile Market Expansion
Trident Group's Heimtextil presentation, themed 'Sustainability in Focus', highlighted bedding and bath collections that blend traditional craftsmanship, modern design, and sustainable innovation. The event also marked Trident's expansion into sustainable product development, featuring a portfolio of eco-friendly products designed to meet the evolving needs of diverse customer segments. Trident Group's Heimtextil presentation, themed 'Sustainability in Focus', highlighted bedding and bath...
PR Newswire
28/01/2025
Datar Cancer Genetics to Provide Groundbreaking Video-Enhanced Results of…
DCG's advanced platform uses human-supervised AI to analyze high-resolution, real-time videos of tumor cells exposed to chemotherapy drugs. These time-lapse videos provide clear, verifiable evidence to support treatment decisions. "For the first time, we can see how a patient's cancer cells respond to various chemotherapy treatments before administration," said Dr. Darshana Patil, Senior Director-Global Strategy and Medical Affairs. DCG's advanced platform uses human-supervised AI to…
PR Newswire
28/01/2025
Commit Biologics announces €5.5m seed financing extension investment by Korys to…
Commit is developing its Bispecific Complement Engaging (BiCE™) platform, which uses single domain antibodies that bind to the complement protein C1q to activate and direct the complement system, a fast-acting and potent part of the innate immune system. BiCE is a modular system that can arm antibodies to direct the complement system in a highly targeted way to selectively kill tumor cells or cells implicated in autoimmune disease. Commit is developing its Bispecific Complement Engaging…
PR Newswire
28/01/2025
In line with its press release dated 19 December 2024, which mentions the…
This project concerns CARBIOS and its subsidiary CARBIOS 54 and could result in the elimination of around 40% of positions.CARBIOS reaffirms its objective to build its PET biorecycling plant in Longlaville after having secured additional funding, in particular non-dilutive financings. Clermont-Ferrand (France), 28 January 2025 (8:30 CET).CARBIOS,(Euronext Growth Paris : ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life...
Nasdaq GlobeNewswire
28/01/2025
New review article highlights Nevisense effectiveness in identifying malignant…
The overarching goal of the review is to summarize the clinical potential of state-of-the-art impedance-based technologies, explaining distinct electrical signatures inherent to cancer vs healthy tissues. These techniques offer real-time insights into tumor dynamics, paving the way for precision-guided therapeutic interventions. The overarching goal of the review is to summarize the clinical potential of state-of-the-art impedance-based technologies, explaining distinct electrical signatures...
PR Newswire
28/01/2025
Orion publishes Financial Statement Release for 2024 and holds a webcast on 25…
ORION CORPORATIONPRESS RELEASE28 JANUARY 2025 at 09.00 EET Orion publishes Financial Statement Release for 2024 and holds a webcast on 25 February 2025 Orion will publish its Financial Statement Release for 2024 on Tuesday, 25 February 2025 at approximately 12.00 noon EET. The release and related presentation material will be available on the company's website at www.orion.fi/en/investors after publishing. Webcast and conference call A webcast and conference call for analysts,...
Nasdaq GlobeNewswire
28/01/2025
OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab…
OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20 thCongress of ECCONANTES, France - January 28 2025, – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), shares details of the three scientific abstracts on its anti-IL-Receptor (IL-7R) Lusvertikimab, which is in clinical development for ulcerative colitis. These abstracts will be presented in Oral Presentation, Digital Oral Presentation and...
Nasdaq GlobeNewswire
28/01/2025
Nicox Announces Scientific Presentation and Conference Attendance in H1 2025
Press ReleaseNicox Announces Scientific Presentation and Conference Attendance in H1 2025 January 28, 2025 – release at 7:30 am CETSophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced a presentation at the upcoming American Glaucoma Society (AGS) Annual Meeting 2025 and participation in a number of key ophthalmology and financial conferences in the first half of 2025. Presentation of...
Nasdaq GlobeNewswire
28/01/2025
Strong sales growth for Cresemba and Zevtera trigger further milestone payments…
Allschwil, Switzerland, January 28, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that the sales in 2024 of the antifungal Cresemba ®(isavuconazole) and the antibiotic Zevtera ®(ceftobiprole) exceeded thresholds triggering sales milestone payments from distribution partners to Basilea, in the total amount of approximately CHF 2...
Nasdaq GlobeNewswire
28/01/2025
Corti Launches Specialized Healthcare AI Infrastructure, Challenging Industry…
The announcement comes at a pivotal moment for healthcare AI adoption. While 74 percent of healthcare professionals in Europe support AI use in practice, 52 percent say they wouldn't feel confident using current AI solutions in their work. This crisis of confidence has contributed to what industry experts call "pilot paralysis" - widespread AI trials that fail to advance beyond testing due to accuracy, cost, and integration challenges. The announcement comes at a pivotal moment for…
PR Newswire
28/01/2025
Roche's Itovebi demonstrated statistically significant and clinically meaningful…
Updated overall survival (OS) results - a key secondary endpoint - reinforce the significant benefit of the Itovebi TM(inavolisib)-based regimen for patients with advancedPIK3CA -mutated, HR-positive, HER2-negative breast cancer in the first-line setting Primary analysis showed the Itovebi-based regimen reached statistical significance, more than doubling progression-free survival in this patient population1Full OS results from the phase III INAVO120 study will be...
Nasdaq GlobeNewswire
28/01/2025
Asset Prioritization in Pharma Domain: How In-Licensing Led to the Selection of…
The client's indication of interest was Atrial Fibrillation, a common arrhythmia characterized by rapid and irregular beating of the heart's atrial chambers. DelveInsight's Atrial Fibrillation Epidem-based Market Forecast Report assesses that 2.7 to 6.1 million people are affected with Atrial Fibrillation in theUnited States, with its prevalence strongly age-dependent. The estimates suggest that approximately 25% of people aged 40 and above are likely to develop AF during their lifetime. This…
PR Newswire
27/01/2025
Advanced Instruments Releases the OsmoPRO® MAX Automated Osmometer to Enhance…
The OsmoPRO MAX goes beyond providing accurate and precise test results to deliver a complete solution that simplifies the osmolality testing workflow. The instrument delivers increased efficiency through direct sampling from primary tubes without transfer to sample cups, automated barcode scanning to reduce transcription errors, and the capability to upload data to the AdvancedQC peer group program for Advanced Instruments' Protinol® and Renol® matrix-based controls. The OsmoPRO MAX goes...
PR Newswire
27/01/2025
PureHealth acquires Majority Stake in Hellenic Healthcare Group in USD 2.3…
PureHealth partnering with CVC in healthcare investments shows strength in PureHealth's international expansion plan. CVC is a leading global private markets manager with approximately USD 201 billion of assets under management. Funds managed or advised by CVC's private equity strategy are invested in approximately 130 companies worldwide, which have combined annual sales of over USD 166 billion and employ over 610,000 people. PureHealth and CVC will collaborate closely, combining their…
PR Newswire
27/01/2025
KFSHRC Heart Centre: A Leader in Advanced Cardiac Treatments
Revolutionizing care from minimally invasive surgery to comprehensive outpatient services RIYADH, Saudi Arabia, Jan.27, 2025(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) has solidified its position as a regional leader in advanced cardiac care. Its Heart Centre combines cutting-edge technology with exceptional outcomes, making it the top choice for patients from Saudi Arabia, the MENA region, and beyond.Participating at Arab Health 2025, KFSHRC...
Nasdaq GlobeNewswire
27/01/2025
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 27 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under…
Nasdaq GlobeNewswire
27/01/2025
Solvias Opens Center of Excellence for Biologics and Cell & Gene Therapy in…
Equipped with state-of-the art analytical instrumentation, laboratory automation, and advanced digital management systems, the new center offers comprehensive GMP testing for cell and gene therapies, monoclonal antibodies (mAbs), and other biologics, from preclinical stages to commercial release. Equipped with state-of-the art analytical instrumentation, laboratory automation, and advanced digital management systems, the new center offers comprehensive GMP testing forcell and gene therapies,...
PR Newswire
27/01/2025
Seeking Investors: First-in-Class Immunotherapeutics for Cancer
MULTIPLE PROOFS-OF-CONCEPT: Leukemia and Pancreatic Cancers(1)LeukemiaANT308 has shown strong single-agent anti-leukemia activity in 2 mouse models. (2) Pancreatic cancerANT308 has shown synergistic effects with anti-PD-1 checkpoint inhibitors in 3 pancreatic cancer models. MULTIPLE PROOFS-OF-CONCEPT: Leukemia and Pancreatic Cancers(1)Leukemia ANT308 has shown strong single-agent anti-leukemia activity in 2 mouse models. (2) Pancreatic cancer ANT308 has shown synergistic effects with...
PR Newswire
27/01/2025
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License…
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, Alvotech's proposed biosimilar to Simponi ®and Simponi Aria ®(golimumab), which are prescribed to treat a...
Nasdaq GlobeNewswire
27/01/2025
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License…
®and Simponi Aria ®(golimumab), which are prescribed to treat a variety of inflammatory conditions. These are the first U.S. BLA filing acceptances announced for a biosimilar candidate to golimumab. The FDA review process for these applications is anticipated to be completed in the fourth quarter of 2025."This is a significant step towards being able to offer U.S. patients access to biosimilar golimumab," said Joseph McClellan, Chief Scientific Officer of Alvotech. “Our in-house...
Nasdaq GlobeNewswire
27/01/2025
Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast presentation
Oslo, January 27, 2025: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer , invites to a webcast presentation of its fourth quarter 2024 results, on Friday, January 31, 2025 . The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 09:00 CET on Friday, January 31, 2025. The webcast presentation will be available on the Ultimovacs website, and it will be possible to...
Nasdaq GlobeNewswire
27/01/2025
Recalculation of warrants of series TO 2 following rights issue
The terms and conditions for the warrants, including potential adjustments due to future share issues, are available on the Company's website. The terms and conditions for the warrants, including potential adjustments due to future share issues, are available on the Company's website. For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail:
[email protected]
The information was submitted for publication, through the agency of the contact...
PR Newswire
27/01/2025
Harness Therapeutics appoints Dr Heather Preston as Chair and secures new…
Dr Heather Preston, seasoned healthcare investor with over 30 years' experience as a scientist, physician, management consultant, and Board adviser, joins as ChairFunding recognises Harness' significant progress in unexplored targets for CNS disease and accelerates selection of clinical candidate for lead programme (FAN1) in Huntington's DiseaseHarness' unique approach builds on recent research published in Nature Medicine and Cell Cambridge, UK, 27 January 2025:Harness...
Nasdaq GlobeNewswire
27/01/2025
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
COPENHAGEN, Denmark, January 27, 2025– Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 9, 2025 to February 5, 2025. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052,...
Nasdaq GlobeNewswire
27/01/2025
Altri Comunicati
